Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RA-9 是一种高选择性蛋白酶体相关的 DUBs 抑制剂,具有良好的毒性和抗癌活性。它阻断泛素依赖性蛋白降解而不影响 20S 蛋白酶体蛋白水解活性。它诱导卵巢癌细胞内质网应激反应,选择性诱导卵巢癌细胞株和供体原代培养细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 129 | 现货 | ||
5 mg | ¥ 347 | 现货 | ||
10 mg | ¥ 553 | 现货 | ||
25 mg | ¥ 983 | 现货 | ||
50 mg | ¥ 1,530 | 现货 | ||
100 mg | ¥ 2,430 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 379 | 现货 |
产品描述 | RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity. RA-9 selectively induces apoptosis in ovarian cancer cell lines. |
体外活性 | The characterization of RA-9 as a small-molecule inhibitor of proteasome-associated DUBs.?Treatment with RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors.?Loss of cell viability following RA-9 exposure is associated with an unfolded protein response as mechanism to compensate for unsustainable levels of proteotoxic stress. |
体内活性 | In vivo treatment with RA-9 retards tumor growth, increases overall survival, and was well tolerated by the host. |
动物实验 | Mice were inoculated i.p. with 100,000 ES-2 cells (in 100 μl DMEM) stably expressing GFP.?When tumor was detectable (approx.?6 days post inoculation), mice were randomly assigned into two groups receiving RA-9 or 0.9% saline.?Treatment with RA-9 was given i.p. on a one-day on, two-days off schedule.?The control group received the vehicle alone at the same schedule.?Working concentrations of RA-9 (10 mg/ml) were reached by dissolution in Cremophor EL and polyethylene glycol 400 (Sigma).?Prior to each injection RA-9 was further diluted in 0.9% saline (working concentration 1mg/ml).?To monitor for tumor growth, RA-9 treated and control mice were imaged with an IVIS SpectrumCT Pre-clinical in vivo imaging system (PerkinElmer) every other day.?Animals were sacrificed when abdomens became distended to twice normal size. |
分子量 | 365.34 |
分子式 | C19H15N3O5 |
CAS No. | 919091-63-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4 mg/mL (10.95 mM), Sonification and heating to 80℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7372 mL | 13.6859 mL | 27.3718 mL | 68.4294 mL |
5 mM | 0.5474 mL | 2.7372 mL | 5.4744 mL | 13.6859 mL | |
10 mM | 0.2737 mL | 1.3686 mL | 2.7372 mL | 6.8429 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RA-9 919091-63-7 Apoptosis Cell Cycle/Checkpoint DNA Damage/DNA Repair Ubiquitination DUB Unfolded cancer RA 9 DUBs Inhibitor Response Deubiquitinase cells inhibit Protein RA9 ovarian survival inhibitor